Amanda Kathleen Arrington

Interests

No activities entered.

Courses

No activities entered.

Scholarly Contributions

Chapters

• Arrington, A. (2017). Malignant Peritoneal and Retroperitoneal Disorders. In Scientific American Surgery.
• Arrington, A., & Kim, J. (2017). Benign Peritoneal and Retroperitoneal Processes. In Scientific American Surgery. doi:10.2310/7800.2257
• Arrington, A., & Kim, J. (2018). Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Mucinous Tumors of the Gastrointestinal Tract. In Diseases of the Gastrointestinal Oncology.
• Arrington, A., & Kim, J. (2014). Diseases of the Peritoneum and Retroperitoneum. In ACS Surgery.

Journals/Publications

• Arrington, A. K. (2020). The Chicago Consensus Guidelines for peritoneal surface malignancies: Introduction. Cancer, 126(11), 2510-2512.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal surface malignancies of various causes. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. This article serves as an introduction to this effort.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms. Annals of surgical oncology, 27(6), 1753-1760.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of appendiceal neoplasms specifically related to the management of peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. Annals of surgical oncology, 27(6), 1761-1767.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of colorectal cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumors. Annals of surgical oncology, 27(6), 1793-1797.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumor specifically related to peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Annals of surgical oncology, 27(6), 1768-1773.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of gastric cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Annals of surgical oncology, 27(6), 1788-1792.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of neuroendocrine tumors specifically related to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Annals of surgical oncology, 27(6), 1780-1787.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of ovarian neoplasms specifically related to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma. Annals of surgical oncology, 27(6), 1774-1779.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal mesothelioma. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Methodology. Annals of surgical oncology, 27(6), 1741-1742.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal surface malignancies of various causes. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. This article explains the process and methodology of building these guidelines and pathways.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations. Annals of surgical oncology, 27(6), 1798-1804.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for palliative care specifically related to peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on Peritoneal Surface Malignancies: Standards. Annals of surgical oncology, 27(6), 1743-1752.
  More info

  The Chicago Consensus Working Group provides the following multidisciplinary recommendations for the care of patients with peritoneal surface malignancies. This article focuses on the standards of a peritoneal surface malignancy center, standards of billing and coding, standards of operative reports for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, standards of cytoreductive surgery training, and standards of intraoperative chemotherapy preparation. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. Cancer, 126(11), 2534-2540.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of colorectal cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors. Cancer, 126(11), 2566-2570.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of desmoplastic small round cell, breast, and gastrointestinal stromal tumors specifically related to peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases. Cancer, 126(11), 2541-2546.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of gastric cancer specifically as it relates to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. Cancer, 126(11), 2561-2565.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of neuroendocrine tumors specifically related to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer, 126(11), 2553-2560.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of ovarian neoplasms specifically related to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on peritoneal surface malignancies: Methodology. Cancer, 126(11), 2513-2515.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of peritoneal surface malignancies of various causes. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness of the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. This article explains the process and methodology of building these guidelines and pathways.
• Arrington, A. K. (2020). The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations. Cancer, 126(11), 2571-2576.
  More info

  The Chicago Consensus Working Group provides multidisciplinary recommendations for palliative care specifically related to peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K. (2020). The Chicago Consensus on peritoneal surface malignancies: Standards. Cancer, 126(11), 2516-2524.
  More info

  The Chicago Consensus Working Group provides the following multidisciplinary recommendations for the care of patients with peritoneal surface malignancies. This article focuses on the standards of a peritoneal surface malignancy center, standards of billing and coding, standards of operative reports for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, standards of cytoreductive surgery training, and standards of intraoperative chemotherapy preparation. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
• Arrington, A. K., O'Grady, C., Schaefer, K., Khreiss, M., & Riall, T. S. (2020). Significance of Lymph Node Resection After Neoadjuvant Therapy in Pancreatic, Gastric, and Rectal Cancers. Annals of surgery.
  More info

  Gastrointestinal cancers are increasingly being treated with NAT before surgical resection. Currently, quality metrics are linked to the number of LNs resected to determine subsequent treatment and prognosis. We hypothesize that NAT decreases LN metastasis, downstages patients, and decreases overall lymph node yields (LNY) compared to initial surgical resection. With increasing use of NAT, this brings into question the validity of quality metrics.
• Guetter, C. R., McGuire, K. P., Oropallo, A. R., Reyna, C., Arrington, A. K., Santry, H. P., Henry, M. C., Quesenberry, A. C., Huang, E. Y., & , A. P. (2020). Surgical job negotiations: How current literature and expert opinion can inform your strategies. American journal of surgery.
  More info

  Negotiation is an essential professional skill. Surgeons negotiating new roles must consider: 1) career level (e.g., new graduate, mid-career or leadership), 2) practice environment (e.g., academic, private practice), 3) organization (e.g., academic, university-affiliated, specialized center), and 4) work-life needs (e.g., geography, joint recruitment).
• Hamidi, M., Dauch, J., Watson, R., O'Grady, C., Hsu, P., Arrington, A., Riall, T. S., & Khreiss, M. (2020). Outcomes with Preoperative Biliary Stenting After Pancreaticoduodenectomy In the Modern Era. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.
  More info

  Previous studies have documented increased complications following pancreaticoduodenectomy in patients who undergo preoperative biliary stenting (PBS). However, in the modern era, the vast majority of patients with jaundice are stented. We hypothesized that there is no difference in short-term postoperative outcomes between PBS and no PBS in patient with obstructive jaundice undergoing pancreaticoduodenectomy.
• Price, E. T., Coverley, C., Arrington, A., Nfonsam, V. N., Morris-Wiseman, L., & Riall, T. S. (2020). Are We Making an Impact? A Qualitative Program Assessment of the Resident Leadership, Wellbeing, and Resiliency Program for General Surgery Residents. Journal of Surgical Education, 77(3), 508-519.
• Arrington, A. K., & Riall, T. S. (2019). Pancreatic Cancer Lymph Node Status: An Unsolved Problem that Impacts Recommendation Despite Guidelines: In reply to Hyer and colleagues. Journal of the American College of Surgeons, 229(2), 223-224.
• Arrington, A. K., Price, E. T., Golisch, K., & Riall, T. S. (2019). Pancreatic Cancer Lymph Node Resection Revisited: A Novel Calculation of Number of Lymph Nodes Required. Journal of the American College of Surgeons, 228(4), 662-669.
  More info

  Pancreatic cancer is the third leading cause of cancer related deaths in the US. Although lymph node (LN) metastasis is a prognostic indicator, the extent of LN resection is still debated. Our goal was to use the distribution of the ratio of positive to negative LNs to derive a more adequate number of necessary examined LNs based on the target LN threshold (TLNT).
• Bell, N., Arrington, A., Adams, S. A., Jones, M., Sakran, J. V., Mehta, A., & Eberth, J. M. (2019). Incidental Cancer Diagnoses in Trauma Patients: A Case-Control Study Evaluating Long-term Outcomes. The Journal of surgical research, 242, 304-311.
  More info

  This study evaluates whether trauma patients who incidentally learned about a malignancy have similar long-term outcomes as patients who organically learned about their malignancy.
• Guetter, C. R., Williams, B. J., Slama, E., Arrington, A., Henry, M. C., Möller, M. G., Tuttle-Newhall, J. E., Stein, S., & Crandall, M. (2018). Greening the operating room. American Journal of Surgery, 216(4), 683-688.
  More info

  Climate change will affect most populations in the next decades and put the health of billions of people at risk. Health care facilities represent a significant source of pollution around the world and contribute to environmental changes. To address this topic, we performed a review of the available literature on tactics to reduce operating room (OR) waste and the potential of these strategies to impact the environment.
• Wolbert, T., Leigh, E. C., Barry, R., Thompson, E. C., Gress, T., Ajmera, A., & Arrington, A. K. (2018). Later Stage Disease and Earlier Onset of Rectal Cancer: Epidemiology and Outcomes Comparison of Rectal Cancer in a Rural Appalachian Area to State and National Rates. The American surgeon, 84(7), 1229-1235.
  More info

  Although the overall rate of colorectal cancer (CRC) has remained stable, studies have shown an increase in the rate of CRC in young patients (
• Bullard, J. T., Eberth, J. M., Arrington, A. K., Adams, S. A., Cheng, X., & Salloum, R. G. (2017). Timeliness of Treatment Initiation and Associated Survival Following Diagnosis of Non-Small-Cell Lung Cancer in South Carolina. Southern medical journal, 110(2), 107-113.
  More info

  Non-small-cell lung cancer (NSCLC) patient survival depends on a number of factors, including early diagnosis and initiation of treatment. Standard treatment options for patients with NSCLC include surgery, radiation therapy, and chemotherapy. The objective of this study was to evaluate the impact that the initiation of timely treatment has on patient survival among a cohort of privately insured patients with NSCLC in South Carolina.
• Torzilli, G., Nagino, M., Tzeng, C. D., Kingham, T. P., Alatise, O. I., Ayandipo, O. O., Yamashita, S., Arrington, A. K., Kim, J., Chun, Y. S., & Vauthey, J. N. (2017). SSAT State-of-the-Art Conference: New Frontiers in Liver Surgery. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 21(1), 175-185.
  More info

  ᅟ.
• Choi, A. H., Arrington, A., Falor, A., Nelson, R. A., Lew, M., Chao, J., Lee, B., & Kim, J. (2016). Assessment of the Double-Staple Technique for Esophagoenteric Anastomosis in Gastric Cancer. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 20(4), 688-92.
  More info

  Reports on outcomes after double-staple technique (DST) for total and proximal gastrectomy are limited, originating mostly from Asian centers. Our objective was to examine anastomotic leak and stricture with DST for esophagoenteric anastomosis in gastric cancer patients.
• Khelfa, Y., Alsharedi, M., Mehmi, I., Raufi, A., Arrington, A., Lebowicz, Y., & Pacioles, T. (2016). Metastatic Sarcomatoid Carcinoma of the Small Intestine: a Case Report of Rare Tumor with Literature Review. Journal of gastrointestinal cancer, 47(4), 478-481.
• Bell, N., Arrington, A., & Adams, S. A. (2015). Census-based socioeconomic indicators for monitoring injury causes in the USA: a review. Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention, 21(4), 278-84.
  More info

  Unlike the UK or New Zealand, there is no standard set of census variables in the USA for characterising socioeconomic (SES, socioeconomic status) inequalities in health outcomes, including injury. We systematically reviewed existing US studies to identify conceptual and methodological strengths and limitations of current approaches to determine those most suitable for research and surveillance.
• Choi, A. H., Nelson, R. A., Schoellhammer, H. F., Cho, W., Ko, M., Arrington, A., Oxner, C. R., Fakih, M., Wong, J., Sentovich, S. M., Garcia-Aguilar, J., & Kim, J. (2015). Accuracy of computed tomography in nodal staging of colon cancer patients. World journal of gastrointestinal surgery, 7(7), 116-22.
  More info

  To predict node-positive disease in colon cancer using computed tomography (CT).
• Wang, Y., Han, E., Xing, Q., Yan, J., Arrington, A., Wang, C., Tully, D., Kowolik, C. M., Lu, D. M., Frankel, P. H., Zhai, J., Wen, W., Horne, D., Yip, M. L., & Yim, J. H. (2015). Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells. Cancer letters, 358(2), 170-9.
  More info

  Baicalein is a natural flavone that exhibits anticancer properties. Using microarrays we found that DDIT4 was the highest transcript induced by baicalein in cancer cells. We confirmed in multiple cancer cell lines large, dose-related expression of DDIT4 by quantitative RT-PCR and immunoblot, which correlates with growth inhibition. Time course experiments demonstrate that DDIT4 is rapidly inducible, with high expression maintained for several days in vitro. Induction of DDIT4 expression is p53 independent based on evaluation of p53 knockout cells. Since DDIT4 is known to inhibit mTORC1 activity we confirmed that baicalein suppresses phosphorylation of mTORC1 targets. Using RNA interference we demonstrate that mTORC1 activity and growth inhibition by baicalein is attenuated by knockdown of DDIT4. We furthermore demonstrate suppression of established tumors by baicalein in a mouse model of breast cancer with increased DDIT4 expression in the tumors. Finally, we demonstrate that baicalein upregulates DDIT4 and causes mTORC1 and growth inhibition in platinum resistant cancer cells in marked contrast to platinum chemotherapy treatment. These studies demonstrate that baicalein inhibits mTORC1 through DDIT4 expression, and may be useful in cancer chemotherapy and chemoprevention.
• Arrington, A. K., & Kim, J. (2014). Data from ACS NSQIP on CRS-HIPEC: can they cool off the controversies?. JAMA surgery, 149(2), 176.
• Arrington, A. K., Goldstein, L., Kruper, L., Vito, C., Yim, J., & Chen, S. L. (2014). Life expectancy after curative-intent treatment of breast cancer: impact on long-term follow-up care. The American surgeon, 80(6), 604-9.
  More info

  Long-term survival rates after treatment for breast cancer are directly influenced by early deaths resulting from disease. For longer-term breast cancer survivors, survival rates appear deceptively low. We hypothesize that the actual survival curve for long-term survivors approaches the overall survival of the general population. The Surveillance, Epidemiology, and End Results database (1988 to 2002) was used to identify patients with nonmetastatic breast cancer who underwent definitive surgical treatment. The survival of the general population was constructed by using national life tables with an age-matched population. Comparisons of survivals were made for 3-, 5-, and 7-year breast cancer survivor cohorts. Of 237,180 patients, 92.4 per cent survived three years, 82.1 per cent five years, and 58.1 per cent seven years. Stage I patients have equivalent or better survivals compared with the age-matched general population in all three cohorts. Stage II patients reached equivalent conditional survival between eight and nine years after diagnosis regardless of cohort. Stage III patients required achieving nine to 10 years after diagnosis to achieve equivalent survival probability, except in 7-year survivors, in whom 10 to 11 years was required. In all stages, once equivalence was reached, survival exceeded the general population over the remaining years. Initial cancer stage influences overall survival for many years after diagnosis. Patients with Stage I cancer return to the general population risk as early as three years after diagnosis, whereas higher stages can require up to nine years to achieve parity with a more generalized population. These findings should be factored into general health screening issues for long-term breast cancer survivors.
• Arrington, A. K., Voci, A., Reparaz, L., & Fry, W. (2014). Factors and outcomes associated with surgical treatment options of contralateral breast cancer. American journal of surgery, 208(4), 524-30.
  More info

  The treatment for a contralateral breast cancer (CBC) presents a growing dilemma given the expanding number of long-term survivors. We hypothesize that there will be specific surgical treatment trends with demographic differences between the treatment groups.
• Arrington, A., Voci, A., Reparaz, L., & Fry, W. (2014). Factors Associated with Surgical Treatment of Contralateral Breast Cancers. American journal of surgery, 208(4), 524-30.
• Eberth, J. M., Qiu, R., Adams, S. A., Salloum, R. G., Bell, N., Arrington, A. K., Linder, S. K., & Munden, R. F. (2014). Lung cancer screening using low-dose CT: the current national landscape. Lung cancer (Amsterdam, Netherlands), 85(3), 379-84.
  More info

  Although the National Lung Screening Trial (NLST) lauds the efficacy of low-dose computed tomography (LDCT) at reducing lung cancer mortality, it has not been widely used for population-based screening. By examining the availability of U.S. LDCT screening centers, and underlying rates of lung cancer incidence, mortality, and smoking prevalence, the need for additional centers may be determined.
• Kim, J., KO, M., Nelson, R., Arrington, A., Luu, C., Falor, A., Nissen, N., Colquhuon, S., Hurria, A., & Singh, G. (2014). An Investigation of Increasing Age and Survival after Orthotopic Liver Transplantation for Patients with Hepatocellular Cancer. Journal of the American College of Surgeons, 218(3), 431-8.
• Kim, J., Ko, M. E., Nelson, R. A., Arrington, A., Luu, C., Falor, A. E., Nissen, N. N., Colquhoun, S., Hurria, A., & Singh, G. (2014). Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer. Journal of the American College of Surgeons, 218(3), 431-8.
  More info

  Orthotopic liver transplantation (OLT) is the gold standard treatment for patients with early hepatocellular carcinoma (HCC). There are concerns about the efficacy of OLT for HCC in older patients, who we hypothesized might have poorer outcomes. Therefore, we sought to examine advanced age and its impact on OLT outcomes.
• Luu, C., Arrington, A. K., Falor, A., Kim, J., Lee, B., Nelson, R., Singh, G., & Kim, J. (2014). Impact of gastric cancer resection on body mass index. The American surgeon, 80(10), 1022-5.
  More info

  Major gastric resection alters digestive function and may lead to profound weight loss. The objective of our study was to evaluate trends in body weight loss after curative gastrectomy for malignancy. A review of patients who underwent gastrectomy from 1999 to 2012 at two institutions was conducted. Patient demographics and treatment were assessed. Student's t test and analysis of variance were used to compare groups. Of 168 patients, two patients (1.2%) were Stage 0, 73 (43.5%) Stage I, 46 (27.4%) Stage II, 45 (26.8%) Stage III, and two (1.2%) stage unknown. Fifty-eight patients (34.5%) underwent total gastrectomy with Roux-en-Y esophagojejunostomy and 110 patients (65.5%) underwent subtotal gastrectomy. The average per cent decreases in body mass index (BMI) postgastrectomy at one month, six months, 12 months, and 24 months were 7.6, 11.7, 11.5, and 11.1 per cent, respectively (P = 0.003). The decreases in BMI were the same for all time periods whether patients had subtotal or total gastrectomy. Weight loss after gastric cancer resection is an important measure of quality of life. By understanding patterns of weight change after gastrectomy, we can better counsel and prepare our patients for the long-term effects of gastric cancer surgery.
• Arrington, A. K., Kruper, L., Vito, C., Yim, J., Kim, J., & Chen, S. L. (2013). Rural and urban disparities in the evolution of sentinel lymph node utilization in breast cancer. American journal of surgery, 206(5), 674-81.
  More info

  Sentinel lymph node biopsy (SLNB) has become the preferred method for axillary nodal staging. The authors examined SLNB utilization in urban versus rural settings as this procedure was adopted and hypothesized that SLNB rates among urban populations increased faster, while the technology shift and acceptance of SLNB were slower at rural centers.
• Arrington, A. K., Nelson, R. A., Falor, A., Luu, C., Wiatrek, R. L., Fakih, M., Singh, G., & Kim, J. (2013). Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World journal of gastrointestinal surgery, 5(6), 178-86.
  More info

  To examine surgical and medical outcomes for patients with cholangiocarcinoma using a population-based cancer registry.
• Arrington, A. K., Nelson, R., Patel, S. S., Luu, C., Ko, M., Garcia-Aguilar, J., & Kim, J. (2013). Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma. World journal of gastrointestinal surgery, 5(12), 321-8.
  More info

  To evaluate the timing of chemotherapy in gastric cancer by comparing survival outcomes in treatment groups.
• Ellimoottil, C., Leichtle, S. W., Wright, C. J., Fakhro, A., Arrington, A. K., Chirichella, T. J., & Ward, W. H. (2013). Online physician reviews: the good, the bad and the ugly. Bulletin of the American College of Surgeons, 98(9), 34-9.
• Falor, A., Arrington, A. K., Luu, C., Schoellhammer, H. F., Ko, M., Chow, W., D'Apuzzo, M., Park, J., & Kim, J. (2013). Massive intra-abdominal imatinib-resistant gastrointestinal stromal tumor in a 21-year-old male. Case reports in medicine, 2013, 373981.
  More info

  Gastrointestinal stromal tumors (GISTs) in adolescence are far less common than adult GISTs and have varied GIST genotypes that present diagnostic and therapeutic challenges. Here, we discuss a 21-year-old male with diagnosis of unresectable, imatinib-resistant GIST. At initial evaluation, a neoadjuvant treatment approach was recommended. As such, the patient received imatinib over the course of one year. Unfortunately, the GIST increased in size, and a subsequent attempt at surgical resection was aborted fearing infiltration of major vascular structures. The patient was then referred to our institution, at which time imatinib therapy was discontinued. Surgical intervention was again considered and the patient underwent successful resection of massive intra-abdominal GIST with total gastrectomy and Roux-en-Y esophagojejunostomy. Since pediatric GISTs are typically resistant to imatinib, we performed genotype analysis of the operative specimen that revealed KIT mutations associated with imatinib sensitivity and resistance. Given the sequencing data and operative findings, the patient was started postoperatively on sunitinib. This case illustrates the importance of understanding both adult and pediatric GISTs when implementing appropriate treatment regimens. Since the genotype of GISTs dictates phenotypic behavior, mutational analysis is an important component of care especially for adolescents whose disease may mirror the pediatric or adult population.
• Heinrich, E. L., Arrington, A. K., Ko, M. E., Luu, C., Lee, W., Lu, J., & Kim, J. (2013). Paracrine Activation of Chemokine Receptor CCR9 Enhances The Invasiveness of Pancreatic Cancer Cells. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 6(3), 241-5.
  More info

  Chemokine receptors mediate cancer progression and metastasis. We have previously examined chemokine receptor CCR9 expression in pancreatic cancer. Here, our objective was to evaluate pancreatic stellate cells (PSCs) as a source of CCL25, the CCR9 ligand, and as an activator of CCL25-CCR9 signaling in pancreatic cancer cells. CCL25 and CCR9 expression levels in human pancreatic cancer tissues and normal human pancreas were assessed by immunohistochemsitry. In vitro secretion of CCL25 in PSCs and PANC-1 cells was verified by enzyme-linked immunosorbent assay. Pancreatic cancer cell invasion was measured using a modified Boyden chamber assay with CCL25, PSC secreted proteins, and PANC-1 secreted proteins as the chemoattractant. There was immunostaining for CCR9 expression in human pancreatic tumor tissues, but not in normal pancreatic tissue. CCL25 expression was absent in the normal pancreatic tissue sample, but was observed in cancer cells and in the stromal cells surrounding the tumor. In vitro, both PANC-1 cells and PSCs secreted CCL25. In an invasion assay, exposure to CCL25, PSC- and PANC-1-conditioned media significantly increased the invasiveness of PANC-1 cells. Inclusion of a CCR9-neutralizing antibody in the invasion assay blocked the increase in invading cells elicited by the chemoattractants. Our studies show that pancreatic cancer invasiveness is enhanced by autocrine and paracrine stimulation of CCR9. PSCs in the tumor microenvironment appear to contribute to paracrine activation of CCR9. Investigations into CCR9 as a potential therapeutic target in pancreatic cancer must consider cancer cell autocrine signaling and also paracrine signaling from interactions in the tumor microenvironment.
• Luu, C., Arrington, A. K., Schoellhammer, H. F., Singh, G., & Kim, J. (2013). Targeted therapies in colorectal cancer: surgical considerations. Journal of gastrointestinal oncology, 4(3), 328-36.
  More info

  Colorectal cancer (CRC) is a leading worldwide health concern that is responsible for thousands of deaths each year. The primary source of mortality for patients with CRC is the development and subsequent progression of metastatic disease. The most common site for distant metastatic disease is the liver. Although patients with metastatic disease to the liver have several effective treatment options, the only one for cure remains surgical resection of the liver metastases. Historically, most patients with liver metastases have had unresectable disease, and only a small percentage of patients have undergone complete curative resection. However, improved systemic therapies have led to an evolution in strategies to treat metastatic CRC to the liver. Under most conditions the management of these patients remains complex; and as chemotherapy options and new targeted therapies continue to improve outcomes, it is clear that a multidisciplinary approach must be the foundation on which advanced surgical and medical techniques are employed. Here, in this review, we highlight the role of targeted therapies in the surgical management of patients with metastatic CRC to the liver.
• Luu, C., Heinrich, E. L., Duldulao, M., Arrington, A. K., Fakih, M., Garcia-Aguilar, J., & Kim, J. (2013). TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells. PloS one, 8(8), e70604.
  More info

  Recent reports have indicated that KRAS and TP53 mutations predict response to therapy in colorectal cancer. However, little is known about the relationship between these two common genetic alterations. Micro-RNAs (miRNAs), a class of noncoding RNA implicated in cellular processes, have been increasingly linked to KRAS and TP53. We hypothesized that lethal-7a (let-7a) miRNA regulates KRAS through TP53. To investigate the relationship between KRAS, TP53, and let-7a, we used HCT116 KRAS(mut) human colorectal cancer cells with four different genotypic modifications in TP53 (TP53(-/-), TP53(+/-), TP53(mut/+), and TP53(mut/-) ). Using these cells we observed that K-Ras activity was higher in cells with mutant or knocked out TP53 alleles, suggesting that wild-type TP53 may suppress K-Ras activity. Let-7a was present in HCT116 KRAS(mut) cells, though there was no correlation between let-7a level and TP53 genotype status. To explore how let-7a may regulate K-Ras in the different TP53 genotype cells we used let-7a inhibitor and demonstrated increased K-Ras activity across all TP53, thus corroborating prior reports that let-7a regulates K-Ras. To assess potential clinical implications of this regulatory network, we examined the influence of TP53 genotype and let-7a inhibition on colon cancer cell survival following chemoradiation therapy (CRT). We observed that cells with complete loss of wild-type TP53 alleles ((-/-) or (-/mut)) were resistant to CRT following treatment with 5-fluorouracil and radiation. Further increase in K-Ras activity with let-7a inhibition did not impact survival in these cells. In contrast, cells with single or double wild-type TP53 alleles were moderately responsive to CRT and exhibited resistance when let-7a was inhibited. In summary, our results show a complex regulatory system involving TP53, KRAS, and let-7a. Our results may provide clues to understand and target these interactions in colorectal cancer.
• Nelson, R., Ko, E. B., Arrington, A., Lee, W., Kim, J., Garcia-Aguilar, J., & Kim, J. (2013). Race and correlations between lymph node number and survival for patients with gastric cancer. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 17(3), 471-81.
  More info

  There is ongoing debate whether extended lymphadenectomy improves survival in gastric cancer patients who undergo surgical resection. We previously observed that Korean-American patients had the highest overall survival in Los Angeles County. Our objective was to assess lymph node (LN) number and its impact on survival for Korean-American gastric cancer patients.
• Armstrong, L., Arrington, A., Han, J., Gavrikova, T., Brown, E., Yamamoto, M., Vickers, S. M., & Davydova, J. (2012). Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy. American journal of surgery, 204(5), 741-50.
  More info

  Oncolytic adenoviruses provide a promising alternative for cancer treatment. Recently, adjuvant interferon (IFN)-alfa has shown significant survival benefits for pancreatic cancer, yet was impeded by systemic toxicity. To circumvent these problems adenovirus with high-level targeted IFN-alfa expression can be generated.
• Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J. (2012). Prognostic and predictive roles of KRAS mutation in colorectal cancer. International journal of molecular sciences, 13(10), 12153-68.
  More info

  The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%-25% of all cancers. In particular, approximately 30%-40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.
• Arrington, A. K., Nelson, R., Chen, S. L., Ellenhorn, J. D., Garcia-Aguilar, J., & Kim, J. (2012). The evolution of surgical technique for total gastrectomy over a 12-year period: a single institution's experience. The American surgeon, 78(10), 1054-8.
  More info

  Despite the wide acceptance of laparoscopic surgical techniques, its use for gastric cancer has been limited. Laparoscopic total gastrectomy poses many technical challenges when compared with open gastrectomy. Our objective was to evaluate our institutional experience and surgical technique for total gastrectomy. Through a review of patients undergoing total gastrectomy (1999 to 2011), 50 patients were identified. During the first decade, 25 per cent of total gastrectomies were performed laparoscopically compared with 77 per cent since 2009. Compared with open cases, laparoscopic cases yielded a significantly higher number of examined lymph nodes (29 vs 19), lower estimated blood loss (200 vs 450 mL), and shorter length of stay (8 vs 14 days). Median operative time, average tumor size, and number of positive lymph nodes were not different. Morbidity rates were much lower in the laparoscopic series; and 30-day mortality rates were similar in both groups. Laparoscopic total gastrectomy and D2 lymphadenectomy are comparable in safety and have improved efficacy than our open total gastrectomy experience. After initiation of a laparoscopic total gastrectomy program in 2009, the majority of cases in our institution are now performed by laparoscopic techniques.
• Patel, S. S., Arrington, A. K., McKenzie, S., Mailey, B., Ding, M., Lee, W., Artinyan, A., Nissen, N., Colquhoun, S. D., & Kim, J. (2012). Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States. International journal of hepatology, 2012, 253517.
  More info

  The application of orthotopic liver transplantation (OLT) for patients with hepatocellular cancer (HCC) necessitates highly selective criteria to maximize survival and to optimize allocation of a scarce resource. The objective of this study was to compare the outcomes of OLT for HCC in patients transplanted under Milan and UCSF criteria. The United Network of Organ Sharing (UNOS) database was queried for patients who had undergone OLT for HCC from 2002 to 2007, and 1,972 patients (Milan criteria, n = 1, 913; UCSF criteria, n = 59) were identified. Patients were stratified by pretransplant criteria (Milan versus UCSF), and clinical and pathologic factors and overall survival were compared. There were no differences in age, gender, diabetes mellitus, body mass index, and hepatitis B, or C status between the two groups. Overall survival was similar between the Milan and UCSF cohorts (1-, 2-, 3-, and 4-year survival rates: 88%, 81%, 76%, and 72% versus 91%, 80%, 68% and 51%, respectively, P = 0.21). Although the number of patients within UCSF criteria was small, our results nevertheless suggest that patients with HCC may have equivalent survival when transplanted under Milan and UCSF criteria. Long-term followup may better determine whether UCSF criteria should be widely adopted.
• Herrington, C. S., Prekker, M. E., Arrington, A. K., Susanto, D., Baltzell, J. W., Studenski, L. L., Radosevich, D. M., Kelly, R. F., Shumway, S. J., Hertz, M. I., Bittner, H. B., & Dahlberg, P. S. (2011). A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation. Clinical transplantation, 25(1), 90-6.
  More info

  Severe primary graft dysfunction (PGD) is the major early problem following lung transplantation. Aprotinin, a serine protease inhibitor, has many anti-inflammatory properties that might reduce or prevent lung injury. Our hypothesis was that the incidence of PGD could be reduced by a combination of donor lung perfusion and systemic administration of aprotinin to recipients.
• Rueth, N. M., McMahon, M., Arrington, A. K., Swenson, K., Leach, J., & Tuttle, T. M. (2011). Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction. Annals of surgical oncology, 18(9), 2515-20.
  More info

  Cancer risk assessment is an important decision-making tool for women considering irreversible risk-reducing surgery. Our objective was to determine the prevalence of BRCA testing among women undergoing bilateral prophylactic mastectomy (BPM) and to review the characteristics of women who choose BPM within a metropolitan setting.
• Tuttle, T. M., Abbott, A., Arrington, A., & Reuth, N. (2010). The increasing use of prophylactic mastectomy in the prevention of breast cancer. Current Oncology Reports, 12(1), 16-21.
• Tuttle, T. M., Abbott, A., Arrington, A., & Rueth, N. (2010). The increasing use of prophylactic mastectomy in the prevention of breast cancer. Current oncology reports, 12(1), 16-21.
  More info

  Selected high-risk women without breast cancer choose to undergo bilateral prophylactic mastectomy (BPM) to reduce their risk of developing the disease. Several studies have reported that BPM significantly reduces, but does not eliminate, breast cancer risk. Few studies have reported rates or trends of BPM use. Patients with unilateral breast cancer are at increased risk for developing cancer in the normal contralateral breast. Some breast cancer patients choose contralateral prophylactic mastectomy (CPM) to prevent cancer in the contralateral breast. The risk of contralateral breast cancer is significantly reduced after CPM. Recent studies reported that CPM rates have markedly increased in recent years in the United States. Alternatives to CPM include surveillance with clinical breast examination, mammography, and, potentially, breast MRI. Endocrine therapy with tamoxifen or aromatase inhibitors significantly reduces the risk of contralateral breast cancer and may be more acceptable than CPM for some patients.
• Arrington, A. K., Dahlberg, P. S., Davydova, J., Vickers, S. M., & Yamamoto, M. (2009). ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas. Surgery, 146(2), 213-9.
  More info

  Although the incidence of adenocarcinoma of the esophageal and gastroesophageal junction has increased at an alarming rate in the past 30 years, little improvement has been made in treatment strategies. Previous studies have demonstrated that many upper gastrointestinal (GI) adenocarcinomas exhibit ERBB2 amplification. In cancers proven to have similar amplification, such as breast, ERBB2-targeted therapies have dramatically improved overall survival and disease-free rates of survival. This study uses siRNA to knockdown ERBB2 in GI adenocarcinoma cell lines to evaluate cell viability, apoptosis, and changes in cell cycle.
• Arrington, A. K., Davydova, J., Vickers, S. M., & Yamamoto, M. (2009). Anti-ERBB2 sh-RNA suppress both cell growth and tumor growth in ERBB2-overexpressing upper gastrointestinal adenocarcinomas. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 13(10), 1754-61.
  More info

  ERBB2 is overexpressed in 15-25% of upper gastrointestinal adenocarcinomas. We use a stable lentiviral shRNA model to demonstrate that ERBB2 suppression in upper gastrointestinal adenocarcinomas with documented ERBB2 amplification effectively decreases ERBB2 protein levels and decreases cell viability. Further, we evaluate tumor growth of cells treated with the ERBB2 shRNA.
• Arrington, A. K., Jarosek, S. L., Virnig, B. A., Habermann, E. B., & Tuttle, T. M. (2009). Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Annals of surgical oncology, 16(10), 2697-704.
  More info

  Patients with unilateral breast cancer have an increased risk of developing contralateral breast cancer. A recent population-based study demonstrated that the proportion of patients with unilateral breast cancer in the United States who underwent contralateral prophylactic mastectomy (CPM) has increased by 150% in recent years. The current study evaluated patients who underwent breast cancer surgery in a metropolitan-based hospital system to determine factors associated with CPM.
• Tuttle, T. M., Arrington, A., & Reuth, N. R. (2009). Increasing contralateral mastectomy use at diagnosis: Surgical prevention of contralateral breast cancer. Current Breast Cancer Reports, 1(3), 162-166.
• Tuttle, T. M., Jarosek, S., Habermann, E. B., Arrington, A., Abraham, A., Morris, T. J., & Virnig, B. A. (2009). Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(9), 1362-7.
  More info

  Some women with unilateral ductal carcinoma in situ (DCIS) undergo contralateral prophylactic mastectomy (CPM) to prevent cancer in the opposite breast. The use and trends of CPM for DCIS in the United States have not previously been reported.
• McCue, J. D., Mooney, J., Quail, J., Arrington, A., Herrington, C., & Dahlberg, P. S. (2008). Ninety-day mortality and major complications are not affected by use of lung allocation score. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 27(2), 192-6.
  More info

  In May 2005 the Organ Procurement Transplant Network (OPTN) and United Network for Organ Sharing (UNOS) implemented the donor lung allocation score (LAS) system to prioritize organ allocation among prospective transplant recipients. The purpose of our study was to determine the impact of LAS implementation on 90-day survival, early complications and incidence of severe primary graft dysfunction (PGD) after the transplant procedure.
• Issaenko, O., Arrington, A., Dahal, G., Bitterman, P., Maddaus, M., & Dahlberg, P. (2007). Targeting Cap-Dependent mRNA Translational Control Pathways in Esophageal Cancer. Journal of Surgical Research, 137(2), 214-5.

Presentations

• Arrington, A., O'Grady, C., Khreiss, M., & Riall, T. S. (2020, April). Significance of Lymph Node Resection After Neoadjuvant Therapy In Pancreatic, Gastric And Rectal Cancers. American Surgical Association Meeting. Washington D.C. *Cancelled due to COVID19 pandemic: American Surgical Association.
  More info

  Arrington AK, O’Grady CL, Khreiss M, Riall TS. Significance of Lymph Node Resection After Neoadjuvant Therapy In Pancreatic, Gastric And Rectal Cancers. 2020 140th American Surgical Association Meeting; Washington DC; April 15-18, 2020. Cancelled due to COVID19 pandemic.
• Arrington, A., O'Grady, C., Khreiss, M., & Riall, T. S. (2020, May). A Tale of Two Cancers: Do Lymph Node Resections Truly Mean the Same in Colon and Rectal Cancers?. Digestive Disease Week. Chicago, IL *Cancelled due to COVID19 pandemic: AASLD | AGA | ASGE | SSAT.
  More info

  Arrington AK, O’Grady CL, Khreiss M, Riall TS. A Tale of Two Cancers: Do Lymph Node Resections Truly Mean the Same in Colon and Rectal Cancers? 2020 Digestive Disease Week; Chicago, Illinois; May 2-5, 2020. Cancelled due to COVID19 pandemic.
• Arrington, A., O'Grady, C., Khreiss, M., & Riall, T. S. (2020, May). Disparities in Receipt of Neoadjuvant Therapy for Gastric and Pancreatic Cancers: The Selection Bias is Real. Digestive Disease Week. Chicago, IL *Cancelled due to COVID19 pandemic: AASLD | AGA | ASGE | SSAT.
  More info

  Arrington AK, O’Grady CL, Khreiss M, Riall TS. Disparities in Receipt of Neoadjuvant Therapy for Gastric and Pancreatic Cancers: The Selection Bias is Real. 2020 Digestive Disease Week; Chicago, Illinois; May 2-5, 2020. Cancelled due to COVID19 pandemic.
• Price, E., Coverley, C., Arrington, A., Aullery, A., Nfonsam, V. N., Morris-Wiseman, L., & Riall, T. S. (2019, Apr 2019). Qualitative Assessment of a Wellbeing and Resiliency Program for General Surgery Residents: Are we making an impact?. 2019 Association for Surgical Education (ASE) Annual Meeting. Chicago, IL: Association for Surgical Education.
• Riall, T. S., Arrington, A., Price, E. T., & Golisch, K. B. (2018, December 5). Pancreatic Cancer Lymph Node Resection Revisited: A Novel Calculation of the Number of Lymph Nodes Required. 2018 Annual Meeting of the Southern Surgical Association. Palm Beach, FL: Southern Surgical Association.
• Arrington, A. (2016, May). Prophylactic Central Neck Dissection—A Step Forward in Treatment.. West Virginia Chapter of American College of Surgeons Annual Meeting. White Sulphur Springs, WV: American College of Surgeons.
• Arrington, A., Schoellhammer, H., Lee, B., Lin, J., Park, J., & Jim, J. (2014, March). Patterns of Lymph Node Disease in Gastric Adenocarcinoma Following D2 Lymph Node Dissection. Central Surgical Association Conference. Indianapolis, IN.
• Bell, N., Arrington, A., & Adams, S. (2014, November). Census-Based Socioeconomic Measures and Injury Risk: A Systematic Review. American Public Health Association Annual Meeting and Exposition. New Orleans, LA.
• Arrington, A., Chow, W., Sato, J., Paz, I., & Tristal, V. (2013, February). Symptom Control in Locally Advanced Soft Tissue Tumors and the Role of Palliative Surgery: Surgery Without Curative Intent. 84th Annual Pacific Coast Surgical Association Meeting. Kauai, HI.
• Arrington, A., Ko, M., Lee, W., Heinrich, E., Nelson, R., & Kim, J. (2013, February). Chemokine Receptor CCR9 is Associated with Poor Clinicopathologic Features in Patients with Gastric Adenocarcinomas. 8th Annual Academic Surgical Congress. New Orleans, LA.
• Arrington, A., Kruper, L., VIto, C., Yim, J., & Chen, S. (2013, January). Life Expectancy After Curative-Intent Surgical Treatment of Breast Cancer. Southern California Chapter of American College of Surgeons. Santa Barbara, CA.
• Arrington, A., Kruper, L., Vito, C., Yim, J., & Chen, S. (2013, March). Lymph Node Evaluation in Early Stage Breast Cancer: Epidemiology and Survival. Society and Surgical Oncology 66th Annual Cancer Symposium. National Harbor, MD.
• Arrington, A., Luu, C., Falor, A., Ko, M., Lee, B., Lin, J., Park, J., & Kim, J. (2013, June). A Clinicopathologic Study on Multifocal Gastric Cancer in a North American Population: Gross and Microscopic Features. 10th International Gastric Cancer Congress. Verona, Italy.
• Arrington, A., Duldulao, M., Pigazzi, A., & Kim, J. (2012, May). Laparoscopic Total Gastroectomy with Multi-Organ Resection for Gastric Cancer. Digestive Disease Week. San Diego, CA.
• Arrington, A., Nelson, R., Chen, S., Ellenhorn, J., & Kim, J. (2012, January). The Evolution of Surgical Technique for Total Gastrectomy Over a 12-Year Period: A Single Institution's Experience. Southern California Chapter of American College of Surgeons. Santa Barbara, CA.
• Arrington, A., Nelson, R., Uyeno, L., Chen, S., Kim, J., & Yim, J. (2012, February). The Disparity in Thyroid Cancer Incidence Between Native South Korean and Korean-American Women. 7th Annual Academic Surgical Congress. Las Vegas, NV.
• Arrington, A., Wang, Y., Yan, J., Akmal, Y., Xing, Q., Wu, T., & Yim, J. (2012, September). Baicalein Induces Tumor in Suppression in Triple Negative Breast Cancer by mTOR Inhibition Medicated Through DDIT4 Expression. American College of Surgeons 98th Annual Clinical Congress. Chicago, IL.
• Guye, M., Nelson, R., Arrington, A., Chen, S., Chow, W., & Kim, K. (2012, January). The Prognostic Significance of Extra-Intestinal Tumor Location for Primary Nonmetastatic Gastrointestinal Stromal Tumors. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco.
• Rueth, N., Arrington, A., Abbott, A., & Tuttle, T. (2010, May). Preoperative Genetic Risk Assessment Among Women Undergoing Bilateral Prophylactic Mastectomy for Cancer Risk-Reduction. American Society of Breast Surgeons 11th Annual Meeting. Las Vegas, NV.
• Arrington, A., Davydova, J., Brown, E., Dahlberg, P., Vickers, S., & Yamamoto, M. (2009, May). Anti-ERBB2 sh-RNA Suppresses Cell Growth in ERBB2-Overexpressing Upper Gastrointestinal Adenocarcinomas. 24th Annual Society for Surgery of the Alimentary Tract Residents and Fellows Research Conference. Chicago, IL.
• Arrington, A., Davydova, J., Brown, E., Dahlberg, P., Vickers, S., & Yamamoto, M. (2009, May). Anti-ERBB2 sh-RNA Suppresses Cell Growth in ERBB2-Overexpressing Upper Gastrointestinal Adenocarcinomas. Digestive Disease Week. Chicago, IL.
• Arrington, A., Davydova, J., Brown, E., Dahlberg, P., Yamamoto, M., & Vickers, S. (2009, February). siRNA based ERBB2 Suppression Decreases Cell Growth in ERBB2-Overexpressing Gastrointestinal Adenocarcinomas. Academic Surgical Congress 4th Annual Meeting. Fort Myers, FL.
• Arrington, A., Davydova, J., Brown, E., Humar, A., Jensen, E., Vickers, S., & Yamamoto, M. (2009, May). Ex Vivo Human Tissue Slicer Model for Evaluating Conditionally Replicative Oncolytic Andenovirus Specificity to Pancreatic Cancer. Digestive Disease Week. Chicago, IL.
• Arrington, A., Jarosek, S., Virnig, B., Habermann, E., & Tuttle, T. (2009, May). Factors Associated with Contralateral Prophylactic Mastectomy Use Among Breast Cancer Patients in Metropolitan Hospital System. Minnesota Surgical Society Spring Conference. St. Paul, MN.
• Arrington, A., Jarosek, S., Virnig, B., Habermann, E., & Tuttle, T. (2009, September). Factors Associated with Contralateral Prophylactic Mastectomy Use Among Breast Cancer Patients. University of Minnesota Women's Health Conference. Minneapolis, MN.
• Arrington, A., Davydova, J., Brown, E., Dahlberg, P., Yamamoto, M., & Vickers, S. (2008, October). siRNA based ERBB2 Supression Decreases Cell Growth in ERBB2-Overexpressing Gastrointestinal Adenocarcinomas. Minnesota Surgical Society Fall Conference. Alexandria, MN.
• Arrington, A., Issaenko, O., Dahal, G., Bitterman, P., Polunovsky, V., Maddaus, M., & Dahlberg, P. (2007, February). Targeting Cap-Dependent mRNA Translational Control Pathways in Esophageal Cancer. Academic Surgical Congress 2nd Annual Meeting. Phoenix, AZ.

Poster Presentations

• Arrington, A., Kruper, L., Vito, C., Yim, J., & Chen, S. (2014, February). Lymph Node Evaluation in Early Stage Breast Cancer: Epidemology and Survival. Academic Surgical Congress , Society of University Surgeons. San Diego, CA.
• Arrington, A., Luu, C., Park, J., Lin, J., Lee, B., & Kim, J. (2014, February). Curative Gastrectomy for Gastric Adenocarcinoma in the Super-Elderly Population: A Single Institution's Experience. Southeastern Surgical Conference. Savannah, GA.
• Bell, N., Arrington, A., & Adams, S. (2014, November). Census-Based Socioeconomic Measures and Injury Risk: A Systematic Review. American Public Health Association Annual Meeting. New Orleans, CA.
• Salloum, R., Cheng, X., Adams, S., Eberth, J., Arrington, A., & Lafata, J. (2014, June). Use of Preventative Services Among Cancer Survivors in the Medicare Program. Academy Health Annual Research Meeting. San Diego, CA.
• Voci, A., Reparaz, L., Fry, W., & Arrington, A. (2014, March). Factors Associated with Surgical Treatment of Second Primary Breast Cancers. Society of Surgical Oncology 67th Annual Cancer Symposium. Phoenix, AZ.
• Arrington, A., Choy, K., Duldulao, M., Luu, C., Sanchez, J., Kim, J., & Garcia-Aguilar, J. (2013, January). Assessment of Macroscopic Features in Relation to Tumor Response to Neoadjuvant Chemoradiation Therapy in Rectal Cancer. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA.
• Arrington, A., Wang, Y., Yan, J., Xing, Q., & Yim, J. (2013, March). Baicalein Induces Tumor Suppression in Triple Negative Breast Cancer while Increasing DDIT4 Expression in an Orthotopic Breast Cancer in vivo Model. Society of Surgical Oncology 66th Annual Cancer Symposium. National Harbor, MD.
• Arrington, A., Arrington, A., Ho, J., Ho, J., Kim, J., Kim, J., Trisal, V., & Trisal, V. (2012, March). Laparoscopic Gastrectomy for Gastric Adenocarcinoma: A Single Institution's Experience and Oncologic Outcomes of 65 Consecutive Patients. Society of Surgical Oncology 65th Annual Cancer Symposium. Orlando, FL.
• Arrington, A., Ho, J., Kim, J., Trisal, V., & Ellenhorn, J. (2012, January). Laparoscopic Gastrectomy for Gastric Adenocarcinoma: A Single Institution's Experience and Oncologic Outcomes of 65 Consecutive Patients. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. San Francisco, CA.
• Arrington, A., Kim, J., Kruper, L., & Chen, S. (2012, March). Rural and Urban Disparities in the Evolution of Sentinel Lymph Node Utilization in Breast Cancer. Society of Surgical Oncology. Orlando, FL.
• Arrington, A., Kruper, L., Vito, C., Yim, J., & Chen, S. (2012, September). Rural and Urban Disparities in the Evolution of Sentinel Lymph Node Utilization in Breast Cancer. American Society of Clinical Oncology (ASCO) Breast Cancer Symposium. San Francisco, CA.
• Arrington, A., London, K., Chen, S. L., Vito, C., Yim, J. H., Nelson, R., & Kruper, L. (2012, November). Patient Factors and Satisfaction in the Choice of Contralateral Prophylactic Mastectomy. 2012 City of Hope Poster Session- Collaboration: Scientific Frontiers and Emerging Therapies. Duarte, CA.
• Arrington, A., London, K., Chen, S., Vito, C., Yim, J., Nelson, R., & Kruper, L. (2012, June). Patient Factors and Satisfaction in the Choice of Contralateral Prophylactic Mastectomy. American Society of Clinical Oncology Annual Meeting 2012. Chicago, IL.
• Arrington, A., London, K., Chen, S., Vito, C., Yim, J., Nelson, R., & Kruper, L. (2012, September). Patient Factors and Satisfaction in the Choice of Contralateral Prophylactic Mastectomy. Association of Women Surgeons Conference. Chicago, IL.
• Guye, M., Nelson, R., Arrington, A., Chen, S., Chow, W., & Kim, K. (2012, January). The Prognostic Significance of Extra-Intestinal Tumor Location for Primary Nonmetastatic Gastrointestinal Stromal Tumors. American Society of Clinical Oncology Gastrointestinal Cancer Symposium. San Francisco, CA.
• Arrington, A., Jarosek, S., Virnig, B., Habermann, E., & Tuttle, T. (2009, May). Factors Associated with Contralateral Prophylactic Mastectomy Use Among Breast Cancer Patients in Metropolitan Hospital System. American Society of Clinical Oncology Annual Meeting. Orlando, FL.
• Arrington, A., Dahlberg, P., Davydova, J., Yamamoto, M., & Vickers, S. (2008, October). ERBB2 Suppression Decreases Cell Growth in ERBB2-Overexpressing Gastrointestinal Adenocarcinomas. Association of Women Surgeons Fall Conference. San Francisco, CA.

Others

• Arrington, A., O'Grady, C., Khreiss, M., & Riall, T. S. (2020, May). A Tale of Two Cancers: Do Lymph Node Resections Truly Mean the Same in Colon and Rectal Cancers?. Gastroenterology; Volume 158, Issue 6, Supplement 1: S-1539-S-1540.
  More info

  Presented at 61st Annual Meeting, Society for Surgery of the Alimentary Tract (SSAT); May 2-5, 2020; Chicago, IL
• Arrington, A., O'Grady, C., Khreiss, M., & Riall, T. S. (2020, May). Disparities in Receipt of Neoadjuvant Therapy for Gastric and Pancreatic Cancers: The Selection Bias is Real. Gastroenterology; Volume 158, Issue 6, Supplement 1: S-1486.
  More info

  Presented at 61st Annual Meeting, Society for Surgery of the Alimentary Tract (SSAT); May 2-5, 2020; Chicago, IL
• Dauch, J., Khreiss, M., O'Grady, C., Hsu, C., Arrington, A., & Riall, T. S. (2020, May). The Impact of Frailty on Patients Undergoing Liver Resection for Hepocellular Carcinoma: A Review of the National Surgical Quality Improvement Program. Gastroenterology; Volume 158, Issue 6, Supplement 1: S-1529.
  More info

  Presented at 61st Annual Meeting, Society for Surgery of the Alimentary Tract (SSAT); May 2-5, 2020; Chicago, IL
• Khreiss, M., Dauch, J., O'Grady, C., Hsu, C., Arrington, A., & Riall, T. S. (2020, May). Outcomes with Preoperative Biliary Stenting After Pancreaticoduodenectomy in the Modern Era. Gastroenterology; Volume 158, Issue 6, Supplement 1: S-1536-1537.
  More info

  Presented at 61st Annual Meeting, Society for Surgery of the Alimentary Tract (SSAT); May 2-5, 2020; Chicago, IL
• Voci, A., Reparaz, L., Fry, W., & Arrington, A. (2014, February). Factors Associated with Surgical Treatment of Second Primary Breast Cancers. Annals Surgical Oncology. 21 (Suppl 1): S73-73.
• Arrington, A., Garcia-Aguilar, J., & Duldulao, M. (2013, February). Assessment of Macroscopic Features of Tumor Response to Neoadjuvant Chemoradiation in Rectal Cancer. Journal of Clinical Oncology. 31(4). Suppl S Abstract 507.
• Arrington, A., Ko, M., Lee, W., Heinrich, E., Nelson, R., & Kim, J. (2013, February). Chemokine Receptor CCR9 is Associated With Poor Clinicopathologic Features in Patients with Gastric Adenocarcinoma. Journal of Surgical Research. 179(2):342.
• Arrington, A., Kruper, L., Vito, C., Yim, J., & Chen, S. (2013, February). Lymph Node Evaluation in Early Stage Breast Cancer: Epidemiology and Survival. Annals of Surgical Oncology. 20 (Suppl 1): S41-41.
• Arrington, A., Wang, Y., Yan, J., Xing, Q., & Yim, Y. (2013, February). Baicalein Induces Tumor Suppression in Triple Negative Breast Cancer While Increasing DDIT4 Expression in an Orthotopic Breast Cancer in vivo Model. Annals Surgical Oncology. 20 (Suppl 1): S3-S38.
• Arrington, A., Duldulao, M., Pigazzi, A., & Kim, J. (2012, May). Laparoscopic Total Gastroectomy with Multi-Organ Resection for Large Gastric Cancer. Gastroenterology. 142(5) S1026-S1026.
• Arrington, A., Ho, J., Kim, J., Trisal, V., & Ellenhorn, J. (2012, October). Laparoscopic Gastroectomy for Gastric Adenocarcinoma: A Single Institution's Experience and Oncologic Outcomes of 65 Consecutive Patients. Journal of Clinical Oncology (suppl 4; abstr 79).
• Arrington, A., Kim, J., Kruper, L., & Chen, S. (2012, September). Rural and Urban Disparities in the Evolution of Sentinel Lymph Node Utilization in Breast Cancer. Journal of Clinical Oncology. 30(27): Suppl S Abstract 71.
• Arrington, A., Kim, J., Kruper, L., Vito, C., Yim, J., & Chen, S. (2012, February). Rural and Urban Disparities in the Evolution of Sentinel Lymph Node Utilization in Breast Cancer. Annals of Surgical Oncology. 19 (Suppl 1): S64-S64.
• Arrington, A., London, K., Chen, S., Vito, V., & Kruper, L. (2012, May). Patient Factors and Satisfaction in the Choice of Contralateral Prophylactic Mastectomy. Journal of Clinical Oncology. 30 (15): Suppl. Abstract 1117.
• Arrington, A., Nelson, R., Uyeno, L., Chen, S., Kim, J., & Yim, J. (2012, February). The Disparity in Thyroid Cancer Incidence Between Native South Korean and Korean-American Women. Journal of Surgical Research. 172 (2):195.
• Arrington, A., Wang, Y., Yan, J., Xing, Q., & Yim, J. (2012, September). Baicalein Induces Tumor Suppression in Triple Negative Breast Cancer by mTOR Inhibition Mediated Through DDIT4 Expression. Journal of the American College of Surgeons 215 (3): Suppl S. S125-S125.
• Guye, M., Nelson, R., Arrington, A., Chen, S., WA, C., & Kim, J. (2012, October). The Prognostic Significance of Extra-Intestinal Tumor Location for Primary Nonmetastatic Gastrointestinal Stromal Tumors. Journal of Clinical Oncology (suppl 4: abstr 2).
• Arrington, A., Davydova, J., Brown, E., Humar, A., Jensen, E., Vickers, S., & Yamamoto, M. (2009, January). Human Tissue Slice Model for Evaluating Conditionally Replicative Oncolytic Adenovirus Specificity to Pancreatic Cancer. Gastroenterology. 136(5). Suppl 1: A 935-A936.
• Arrington, A., Davydova, K., Vickers, S., & Yamamoto, M. (2009, May). Anti-ERBB2 si- and sh-RNAs Suppress Cell Growth in ERBB2-Overexpressing Upper Gastrointestinal Adenocarcinomas. Gastroenterology. 136(5). Suppl 1. A875-A875.
• Arrington, A., Jarosek, S., Virnig, B., Habermann, E., & Tuttle, T. (2009, May). Factors Associated with Contralateral Prophylactic Mastectomy Use Among Breast Cancer Patients in Metropolitan Hospital System. Journal of Clinical Oncology 27: 15s, (suppl; abstr 6558).